Entrada Therapeutics Inc
TRDA5.550USD
+0.460+9.04%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
211.09MMarket Cap
LossP/E TTM
More Details of Entrada Therapeutics Inc Company
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a class of medicines, which engages intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform (EEV Platform), the Company is building a robust development portfolio of therapeutic candidates. Its first two drug candidates, ENTR-601-44 and VX-670, are in clinical trials. VX-670 for dystrophy type 1 (DM1) is designed to block the triplet repeats in the messenger RNA (mRNA). ENTR-601-44 is in a Phase I clinical trial. The Company also announced the selection of additional clinical candidates within its Duchenne franchise, ENTR-601-45 and ENTR-601-50.
Company Info
Ticker SymbolTRDA
Company nameEntrada Therapeutics Inc
IPO dateOct 29, 2021
CEOMr. Dipal Doshi
Number of employees183
Security typeOrdinary Share
Fiscal year-endOct 29
AddressOne Design Center Place
CityBOSTON
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code02210
Phone18573051825
Websitehttps://www.entradatx.com/
Ticker SymbolTRDA
IPO dateOct 29, 2021
CEOMr. Dipal Doshi
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Peter S. Kim, Ph.D.
Dr. Peter S. Kim, Ph.D.
Director
Director
104.33K
-10.60%
Dr. Natarajan Sethuraman, Ph.D.
Dr. Natarajan Sethuraman, Ph.D.
President of Research and Development
President of Research and Development
80.48K
-2.14%
Mr. Kory James Wentworth, CPA
Mr. Kory James Wentworth, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
30.11K
-5.45%
Mr. Nathan J. Dowden
Mr. Nathan J. Dowden
President, Chief Operating Officer
President, Chief Operating Officer
10.05K
-14.80%
Ms. Gina Chapman
Ms. Gina Chapman
Independent Director
Independent Director
--
--
Dr. Bernhardt (Bernie) Zeiher, M.D.
Dr. Bernhardt (Bernie) Zeiher, M.D.
Independent Director
Independent Director
--
--
Dr. Kush M. Parmar, M.D., Ph.D.
Dr. Kush M. Parmar, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Dipal Doshi
Mr. Dipal Doshi
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Mary T. Thistle, CPA
Ms. Mary T. Thistle, CPA
Independent Director
Independent Director
--
--
Dr. Mahalakshmi (Maha) Radhakrishnan, M.D.
Dr. Mahalakshmi (Maha) Radhakrishnan, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Peter S. Kim, Ph.D.
Dr. Peter S. Kim, Ph.D.
Director
Director
104.33K
-10.60%
Dr. Natarajan Sethuraman, Ph.D.
Dr. Natarajan Sethuraman, Ph.D.
President of Research and Development
President of Research and Development
80.48K
-2.14%
Mr. Kory James Wentworth, CPA
Mr. Kory James Wentworth, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
30.11K
-5.45%
Mr. Nathan J. Dowden
Mr. Nathan J. Dowden
President, Chief Operating Officer
President, Chief Operating Officer
10.05K
-14.80%
Ms. Gina Chapman
Ms. Gina Chapman
Independent Director
Independent Director
--
--
Dr. Bernhardt (Bernie) Zeiher, M.D.
Dr. Bernhardt (Bernie) Zeiher, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q1
FY2024
FY2023
FY2023Q2
No Data
By RegionUSD
Name
Revenue
Proportion
United States
20.56M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Jul 18
Updated: Fri, Jul 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
12.79%
MPM Capital Inc.
11.52%
5AM Ventures
11.19%
F. Hoffman La Roche, Ltd.
6.75%
T. Rowe Price Associates, Inc.
6.65%
Other
51.10%
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
12.79%
MPM Capital Inc.
11.52%
5AM Ventures
11.19%
F. Hoffman La Roche, Ltd.
6.75%
T. Rowe Price Associates, Inc.
6.65%
Other
51.10%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
26.79%
Investment Advisor
21.58%
Hedge Fund
15.41%
Corporation
11.33%
Venture Capital
11.32%
Private Equity
2.00%
Individual Investor
0.97%
Research Firm
0.73%
Pension Fund
0.19%
Other
9.69%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
226
35.35M
92.97%
-1.79M
2025Q1
237
37.05M
97.63%
-2.01M
2024Q4
222
37.20M
98.96%
+761.72K
2024Q3
209
35.09M
95.11%
-779.91K
2024Q2
193
34.68M
94.55%
+2.42M
2024Q1
185
31.33M
93.34%
-1.07M
2023Q4
174
31.30M
93.83%
-1.07M
2023Q3
167
31.14M
93.63%
-973.86K
2023Q2
154
30.75M
92.59%
+53.89K
2023Q1
141
30.00M
92.19%
-903.00K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Baker Bros. Advisors LP
4.87M
12.82%
--
--
Mar 31, 2025
MPM Capital Inc.
4.38M
11.54%
--
--
Mar 31, 2025
5AM Ventures
4.31M
11.35%
-100.00K
-2.27%
Jun 30, 2025
F. Hoffman La Roche, Ltd.
2.57M
6.77%
-175.00K
-6.38%
Dec 31, 2024
T. Rowe Price Associates, Inc.
2.70M
7.11%
-167.02K
-5.83%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.73M
4.56%
+55.00
+0.00%
Mar 31, 2025
Merck & Co Inc
1.74M
4.58%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
1.57M
4.14%
+111.36K
+7.62%
Mar 31, 2025
Janus Henderson Investors
2.12M
5.59%
+41.29K
+1.98%
Mar 31, 2025
Wellington Management Company, LLP
1.05M
2.78%
+21.49K
+2.08%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
